Analyst Group

Analyst Group Comment on Circio’s New circVec Data at ASGCT 2026: Reduced Cellular Stress Adds a New Safety Dimension

Källa: MFN
Positiv

Sammanfattning

Analyst Group kommenterar ny data från Circio gällande deras circVec-teknologi presenterad vid ASGCT. Gruppen anser att den nya datan, som fokuserar på minskad cellulär stress och förbättrad hjärtprestanda, stärker bolagets säkerhetsprofil och partnerskapspotential.

Analys

Analyst Group bedömer att den presenterade datan vid ASGCT är mer analytiskt betydelsefull än tidigare uttrycksmultipelfynd. Den nya datan kring UPR/cellulär stress stärker circVecs säkerhetsprofil. Förbättrad hjärtprestanda med circVec 4.0, bred cellulär täckning vid låg dos och en hjärtspecifik dosbesparingskurva, nu underbyggd på RNA-nivå, stärker grunden för kommande avläsningar. ASGCT-forumet ger ökad synlighet och stärker både den vetenskapliga grunden och partnerskapsmomentumet.

Insikter

  • • Analyst Group anser att den nya datan är mer analytiskt betydelsefull än tidigare uttrycksmultipelfynd.
  • • Fokus på säkerhetsprofilen (cellulär stress) adderar en ny dimension till teknologin.
  • • Stärkt partnerskapsmomentum som en följd av den presenterade datan och forumet.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 15th of May 2026, the publication of an extensive new circVec-AAV data package presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, 11–15 May 2026. The materials comprise a poster presentation on 13 May detailing in vivo cardiac findings and an oral presentation by CEO Dr. Erik D. Wiklund on 15 May providing a platform-level overview.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 15th of May 2026, the publication of an extensive new circVec-AAV data package presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, 11–15 May 2026. The materials comprise a poster presentation on 13 May detailing in vivo cardiac findings and an oral presentation by CEO Dr. Erik D. Wiklund on 15 May providing a platform-level overview.

In summary, Analyst Group views the ASGCT data package as analytically more meaningful than a repetition of previously announced expression multiples. The expanded UPR/cellular stress data reinforces circVec’s safety profile, while the stronger heart performance with circVec 4.0, the broad cellular coverage at low dose, and the heart-specific dose-sparing curve, now substantiated at the RNA transcript level, reinforce the basis for the H2-26 disease-model readouts. Combined with the visibility provided by the ASGCT forum itself, the package strengthens both the scientific foundation and the partnering momentum of the licensing narrative.

Read Analyst Groups comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.